Laura Towart and Aaron Leibtag: 6 Years, One Early Bet, and a Collaboration That Changed Patient Care
Laura Towart and Aaron Leibtag

Laura Towart and Aaron Leibtag: 6 Years, One Early Bet, and a Collaboration That Changed Patient Care

Laura Towart, Founder and CEO at Vivan Therapeutics, shared a post by Aaron Leibtag, Head, Global Health Systems AI Strategy Pursuits at HEALWELL AI, on LinkedIn, adding:

“Thanks Aaron it was so good to see you after all these years. I walked away thinking how incredible it was that we met up in Manchester at a Eureka Network Quantum Technologies program matchmaking event 6 years ago. Our collaboration work pushed early boundaries of generating valuable insights from existing datasets, including information, organization, access, deploying tools in protected datasets etc (thanks to Genomics England).

The funding we received laid the foundation for TuMatch lung, our clinical decision support software for rapid, personalized treatment guidance. It has been a long road indeed, and we refused to give up. I’m so happy to see the value you built at Pentavere has found a home with HEALWELL AI (TSX: AIDX) WELL Health Technologies Corp. (TSX: WELL) and your impact on patients has an extended reach. Congratulations my friend- great work!!”

Quoting Aaron Leibtag‘s post:

“Being a digital health founder is hard and those of us who’ve lived the grind share a deep respect for one another. There are few people I respect more than Laura Towart, an exceptional founder and CEO building Vivan Therapeutics to advance truly personalized medicine.

Six years ago, before AI was a buzzword, we were doing the unglamourous work of being early. With support from National Research Council Canada / Conseil national de recherches Canada, Innovate UK, and Genomics England, we set out to combine genomics data with real world clinical data to generate better, more personalized predictions for patients. It wasn’t easy, there was no playbook but we did it.

Catching up at Arab Health in Dubai was sweet. Our smiles, part disbelief, part pride, part joy say it all. Behind them is what matters most: patients whose lives are better because we refused to quit. Thank you IRAP, Innovate UK, and Genomics England, your support helped write a chapter of this story we’re still living.”

Other articles featuring Laura Towart on OncoDaily.